Trial intelligence / Profile preview

Bioavailability of voriconazole in critically ill ICU patients

2014-001222-15Phase 4Active

Sponsor
University Medical Center Groningen
Start
May 2014
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of voriconazole in invasive aspergillosis (IA), sponsored by University Medical Center Groningen. Primary endpoint: Primary: Voriconazole bioavailability < 80%. Started May 2014; status: active.

02

Drugs

voriconazole
03

Conditions

invasive aspergillosis (IA)

Beyond the preview

Go deeper on 2014-001222-15.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-001222-15.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call